Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEA-targeted CAR-T in advanced solid tumors
NCT06006390Phase 2Recruiting
- Sponsor
- Chongqing Precision Biotech
- Start
- Sep 2023
- Primary completion
- Dec 2025
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label trial of C-13-60 in gastric cancer (GC), colon cancer, rectal cancer and 4 more (2 arms), sponsored by Chongqing Precision Biotech. Primary endpoints: Safety of CAR-T cell preparations at 1 month and Recommended dose and infusion regimen at 28 days. Started Sep 2023; status: recruiting.
02
Drugs
C-13-60
03
Conditions
gastric cancer (GC)colon cancerrectal canceresophageal cancerpancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06006390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06006390.